Clinical trial
Effects of F17464 in Acute Exacerbation of Schizophrenia
NCT02151656 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effects of F17464 in Acute Exacerbation of Schizophrenia
- Lead sponsor
- Pierre Fabre Medicament
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 2014
- Completion date
- December 31, 2015
- Enrollment
- 158 (actual)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.